Bioaffinity Technologies Inc (BIAF)

$0.79 -0.28 (-26.04%)
Market Cap 5.13M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.58%
Debt to Equity Ratio 0.02
Volume 358,230
Avg Vol 84,960
Day's Range N/A - N/A
Shares Out 4.50M
Stochastic %K 18%
Beta 2.45
Analysts Strong Buy
Price Target $6.00

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 210 698 5334
Address:
3300 Nacogdoches Road, Suite 216, San Antonio, United States
GraceUnderPressure2112
GraceUnderPressure2112 Feb. 4 at 7:17 PM
$BIAF somebitch!! Probably gonna test 50 cents soon... Im out Good luck every1
0 · Reply
Stonecrest
Stonecrest Feb. 4 at 6:57 PM
$BIAF I wish we were privy to the news. Obviously, somethings going on you. Don’t have this kind of drop with that much volume on a whim. Or at least I don’t think you do. It is such a tiny company that maybe it’s just being manipulated.
0 · Reply
09test08
09test08 Feb. 4 at 6:51 PM
$BIAF dump dump dump. Junk.
0 · Reply
09test08
09test08 Feb. 4 at 5:51 PM
$BIAF the leadership of the company should be committed (mentally)
0 · Reply
artmas92
artmas92 Feb. 4 at 5:38 PM
$BIAF well, for me, I'm pot committed and will ride it to zero lol
1 · Reply
Itinerant
Itinerant Feb. 4 at 5:22 PM
$BIAF WTF is this shit? I really do not trust this CEO, by the way. I can not pin it down, and I do not know what it is, but she gives me the creeps. The tech looks excellent, but she is likely running this like the Donald, for herself and her brother.
0 · Reply
09test08
09test08 Feb. 4 at 5:11 PM
$BIAF 150k that’s how bad they need money. Fucking joke. Absolutely zero respect for shareholders. Trash.
1 · Reply
ka1954
ka1954 Feb. 4 at 5:08 PM
$BIAF down 20% on 150k volume. what if we get 1million volume down 80% ? LOL
0 · Reply
ka1954
ka1954 Feb. 4 at 5:08 PM
$BIAF what dilution? volume only 150k.
0 · Reply
09test08
09test08 Feb. 4 at 4:52 PM
$BIAF fucking joke. Diluting to zero.
1 · Reply
Latest News on BIAF
bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Jan 7, 2026, 8:00 AM EST - 4 weeks ago

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Dec 3, 2025, 8:00 AM EST - 2 months ago

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 8:00 AM EST - 2 months ago

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

Nov 5, 2025, 8:00 AM EST - 3 months ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 28, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Oct 20, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Oct 16, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 15, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 2:00 PM EDT - 4 months ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 1:00 PM EDT - 4 months ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 4 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 3:45 PM EDT - 4 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Oct 7, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:44 PM EDT - 4 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 30, 2025, 12:15 PM EDT - 4 months ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 5:59 PM EDT - 4 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Sep 29, 2025, 3:51 PM EDT - 4 months ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 26, 2025, 8:00 AM EDT - 4 months ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 17, 2025, 8:15 AM EDT - 5 months ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Sep 9, 2025, 8:00 AM EDT - 5 months ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 18, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Appoints New Members to Board of Directors

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 4:15 PM EDT - 6 months ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 14, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Reports Second Quarter 2025 Results

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 9:25 AM EDT - 6 months ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Aug 13, 2025, 8:00 AM EDT - 6 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 22, 2025, 9:00 AM EDT - 7 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 24, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025, 9:00 AM EDT - 9 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025, 9:00 AM EDT - 9 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025, 8:30 AM EDT - 9 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025, 9:00 AM EDT - 9 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:15 PM EDT - 9 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025, 1:00 PM EDT - 9 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 10:30 AM EDT - 9 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025, 9:25 AM EDT - 9 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17, 2025, 9:15 AM EDT - 10 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 31, 2025, 9:28 AM EDT - 11 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26, 2025, 9:00 AM EDT - 11 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 19, 2025, 9:00 AM EDT - 11 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 13, 2025, 9:00 AM EDT - 11 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Mar 6, 2025, 8:00 AM EST - 11 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 12:10 PM EST - 1 year ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 1 year ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 1 year ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 1 year ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 22, 2025, 8:00 AM EST - 1 year ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

GraceUnderPressure2112
GraceUnderPressure2112 Feb. 4 at 7:17 PM
$BIAF somebitch!! Probably gonna test 50 cents soon... Im out Good luck every1
0 · Reply
Stonecrest
Stonecrest Feb. 4 at 6:57 PM
$BIAF I wish we were privy to the news. Obviously, somethings going on you. Don’t have this kind of drop with that much volume on a whim. Or at least I don’t think you do. It is such a tiny company that maybe it’s just being manipulated.
0 · Reply
09test08
09test08 Feb. 4 at 6:51 PM
$BIAF dump dump dump. Junk.
0 · Reply
09test08
09test08 Feb. 4 at 5:51 PM
$BIAF the leadership of the company should be committed (mentally)
0 · Reply
artmas92
artmas92 Feb. 4 at 5:38 PM
$BIAF well, for me, I'm pot committed and will ride it to zero lol
1 · Reply
Itinerant
Itinerant Feb. 4 at 5:22 PM
$BIAF WTF is this shit? I really do not trust this CEO, by the way. I can not pin it down, and I do not know what it is, but she gives me the creeps. The tech looks excellent, but she is likely running this like the Donald, for herself and her brother.
0 · Reply
09test08
09test08 Feb. 4 at 5:11 PM
$BIAF 150k that’s how bad they need money. Fucking joke. Absolutely zero respect for shareholders. Trash.
1 · Reply
ka1954
ka1954 Feb. 4 at 5:08 PM
$BIAF down 20% on 150k volume. what if we get 1million volume down 80% ? LOL
0 · Reply
ka1954
ka1954 Feb. 4 at 5:08 PM
$BIAF what dilution? volume only 150k.
0 · Reply
09test08
09test08 Feb. 4 at 4:52 PM
$BIAF fucking joke. Diluting to zero.
1 · Reply
Quagglerock
Quagglerock Feb. 4 at 4:47 PM
$BIAF Called shaking the tree. Seen it hundreds of times. I know what often happens next.
1 · Reply
Stonecrest
Stonecrest Feb. 4 at 4:42 PM
$BIAF wow something is going on. Up to $1.27 on the patent news and huge crash. Why no PR on the patent?
1 · Reply
WenABVEAudit
WenABVEAudit Feb. 4 at 4:33 PM
$BIAF fuck this. I’m out
0 · Reply
WenABVEAudit
WenABVEAudit Feb. 4 at 4:21 PM
$BIAF BRO WHAT????
0 · Reply
WenABVEAudit
WenABVEAudit Feb. 3 at 8:27 PM
$BIAF shouldn’t the patent allow them to secure 3rd party manufacturing/partnership?
0 · Reply
WenABVEAudit
WenABVEAudit Feb. 3 at 8:27 PM
$BIAF are we going to see a nice run when patent pr is released?
1 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 3 at 6:49 PM
$BIAF Great piece that accurately captures BIAF's current position. So if you want to refresh your understanding of BIAF or learn about BIAF for the first time, this is essential reading. https://everyticker.com/quote/BIAF/analysis/biaf-s-diagnostic-pivot-a-sputum-test-s-race-against-solvency
1 · Reply
CedarFence
CedarFence Feb. 3 at 4:15 PM
$BIAF Yep! That’s great news. Now… let’s use it. The purpose of a patent is to prevent others from making or selling an invention so as to allow the patent holder to PROFIT FROM THE INVENTION.
0 · Reply
artmas92
artmas92 Feb. 3 at 3:14 PM
$BIAF Patent is real, issued today, and verifiable on https://ppubs.uspto.gov/basic/ Search for patent 12,542,215 👍
0 · Reply
WenABVEAudit
WenABVEAudit Feb. 3 at 2:34 PM
$BIAF gotta be kidding me. Good patent news and they drop this like a rock at open?
1 · Reply
M1Tanker
M1Tanker Feb. 2 at 9:51 PM
$BIAF
0 · Reply
M1Tanker
M1Tanker Feb. 2 at 9:24 PM
$BIAF 🙏
1 · Reply